• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Neoprobe presses past controversy, submits Lymphoseek NDA| Regulatory Roundup

Neoprobe presses past controversy, submits Lymphoseek NDA| Regulatory Roundup

August 11, 2011 By MassDevice staff

Neoprobe

Cancer diagnostics firm Neoprobe Corp. (NYSE Amex:NEOP) pressed past the controversy surrounding its Lymphoseek radiopharmaceutical and submitted a new drug application for FDA review.

The Dublin, Ohio-based company hopes to win clearance for Lymphoseek for use in intraoperative lymphatic mapping, a surgical procedure that identifies and biopsies lymph nodes for traces of cancer.

Neoprobe has weathered a storm of criticism, including a citizen’s petition filed by hedge fund MSMB Capital Management asking the FDA to block the new drug application the grounds that the drug’s pivotal trials suffered from vital mistakes, allegations that Neoprobe has officially rebutted.

In its formal response, Neoprobe called the citizen’s petition "baseless and replete with factual and regulatory misstatements, served under a cloak of legitimacy," and called MSMB a "short-seller who could potentially benefit financially from a decline in Neoprobe’s stock price."

"In over 500 subjects receiving Lymphoseek to date," Neoprobe wrote it a recent press release, "no drug-related serious adverse events or clinically significant drug-related adverse events have been reported."

Regulatory Roundup
  • Toshiba lands FDA clearance for 3T MR
    Tustin, Calif.-based Toshiba Medical Systems Corp. touted FDA clearance for its "patient friendly" Vantage Titan 3T open bore MR designed to improve patient compliance and comfort without sacrificing advanced radiology capability. The device boasts noise reduction technology, a wide and open bore, feet-first imaging and proprietary contrast-free techniques.

    Read more
  • Boston Scientific wins expanded indication of WallFlex stent from Canadian regulators
    Natick, Mass.-based Boston Scientific Corp. (NYSE:BSX) announced that it won Canadian approval for an expanded indication on its WallFlex stent, which may now be used to treat benign biliary strictures.
    Read more
  • GE lands FDA clearance for Optima compact CT system
    GE Healthcare announced FDA clearance for its Optima CT660 device, a next-generation compact computer tomography system for a variety of clinical settings, including cardiac, neurological, emergency room and routine CT.

    Read more
  • EDAP wins 510(k) clearance for compact kidney stone pulverizer
    Lyon, France-based EDAP TMS SA (NSDQ:EDAP) won FDA 510(k) clearance for its Sonolith i-move lithotripter, a device that uses shock waves to pulverize kidney stones. The Sonolith device includes an infrared stereo-vision system for real-time, three-dimensional ultrasound location of stones.

    Read more
  • MedShape Solutions gets FDA nod for ankle fusion device
    Atlanta, Ga.-based MedShape Solutions Inc. announced FDA 510(k) clearance for its DynaNail intramedullary ankle fusion nail, which uses shape memory alloy technology to actively adapt to changes such as local bone resorption.

    Read more
  • IntraPace gets European approval for weight-loss device wireless monitoring
    Mountain View, Calif.-based IntraPace Inc. won CE Mark approval in the European Union for a wireless monitoring feature on its abiliti weight-loss device, which, when implanted in a patient, detects eating and drinking habits and sends low-level electrical impulses to the stomach to give a feeling of fullness. The new feature allows patients to wirelessly access data on their eating and drinking habits.

    Read more
  • IntriCon lands 510(k) clearance for diagnostic monitor
    Arden Hills, Minn.-based IntriCon Corp, (NSDQ:IIN) announced FDA 510(k) clearance for its Centauri cardiac diagnostic monitor with wireless transmission of critical patient data.

    Read more
  • BridgePoint Medical lands IDE approval for peripheral chronic total occlusion study
    Minneapolis, Minn.-based BridgePoint Medical Inc. enrolled their first patient into a study of the safety and effectiveness of the company’s devices in chronically occluded arteries in the legs.
    Read more
  • Relievant Medsystems gets FDA approval to begin pivotal study of lower back pain
    Redwood City, Calif.-based Relievant Medsystems Inc. announced that it received FDA approval to begin clinical trials of its Intracept treatment for lower back pain. Intracept uses radiofrequency energy delivered through a small access tube in the lower back to deaden the basivertebral nerve, which is believed to be a big contributor to chronic lower back pain.
    Read more
  • Filed Under: 510(k), Diagnostics, News Well, Oncology Tagged With: Boston Scientific, BridgePoint Medical Inc., EDAP TMS SA, GE Healthcare, IntraPace Inc., IntriCon Corp., MedShape Solutions Inc., MSMB Capital, Navidea Biopharmaceuticals, Regulatory Roundup, Relievant Medsystems Inc., Toshiba

    More recent news

    • A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
    • Dexcom continues advances in AI for CGM, type 2 diabetes awareness
    • Tandem continues to deliver more options, benefits for those with diabetes
    • Breaking: Sequel to launch twiist automated insulin delivery system next month
    • Dexcom shares U.S. report on CGM benefits for type 2 diabetes

    Primary Sidebar

    “md
    EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
    Get the latest med device regulatory, business and technology news.

    DeviceTalks Weekly

    See More >

    MEDTECH 100 Stock INDEX

    Medtech 100 logo
    Market Summary > Current Price
    The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
    MDO ad

    Footer

    MASSDEVICE MEDICAL NETWORK

    DeviceTalks
    Drug Delivery Business News
    Medical Design & Outsourcing
    Medical Tubing + Extrusion
    Drug Discovery & Development
    Pharmaceutical Processing World
    MedTech 100 Index
    R&D World
    Medical Design Sourcing

    DeviceTalks Webinars, Podcasts, & Discussions

    Attend our Monthly Webinars
    Listen to our Weekly Podcasts
    Join our DeviceTalks Tuesdays Discussion

    MASSDEVICE

    Subscribe to MassDevice E-Newsletter
    Advertise with us
    About
    Contact us

    Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
    The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

    Privacy Policy